You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 10,857,161

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,857,161

Title:	Non-hormonal steroid modulators of NF-kB for treatment of disease
Abstract:	Provided herein is a pharmaceutical composition comprising a compound having the structural formula wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.
Inventor(s):	John M. McCall, Eric Hoffman, Kanneboyina Nagaraju
Assignee:	Reveragen Biopharma Inc
Application Number:	US16/226,061
Patent Claims:	1. An oral pharmaceutical composition comprising a compound having the structural formula comprising a therapeutically effective amount of the compound in a suspension. 2. The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is between 10 mg to 200 mg of the compound. 3. The pharmaceutical composition of claim 1, wherein the composition is formulated as a tablet or capsule. 4. The pharmaceutical composition of claim 1, wherein the suspension further comprises a flavoring agent. 5. The pharmaceutical composition of claim 1, wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. 6. The pharmaceutical composition of claim 5, wherein the muscular dystrophy is chosen from Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. 7. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is Duchenne muscular dystrophy. 8. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is Becker muscular dystrophy. 9. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is limb girdle muscular dystrophy. 10. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is congenital muscular dystrophy. 11. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is facioscapulohumeral muscular dystrophy. 12. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is myotonic muscular dystrophy. 13. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is oculopharyngeal muscular dystrophy. 14. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is distal muscular dystrophy. 15. The pharmaceutical composition of claim 6, wherein the muscular dystrophy is Emery-Dreifuss muscular dystrophy. 16. A method of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound having the structural formula wherein the therapeutically effective amount is between 10 mg to 200 mg. 17. The method of claim 16, wherein the compound is administered orally. 18. The method of claim 17, wherein the compound is administered as a solution or suspension. 19. The method of claim 18, wherein the solution or suspension further comprises a flavoring agent. 20. The method of claim 16, wherein the muscular dystrophy is chosen from Duchenne muscular dystrophy, Becker muscular dystrophy, limb girdle muscular dystrophy, congenital muscular dystrophy, facioscapulohumeral muscular dystrophy, myotonic muscular dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophy, and Emery-Dreifuss muscular dystrophy. 21. A method of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound having the structural formula wherein the therapeutically effective amount is between 0.01 mg/kg to 10.0 mg/kg.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.